BoneKEy Reports | Original Article
Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing’s syndrome
Zhanna E Belaya
Alexander V Iljin
Galina A Melnichenko
Alexander G Solodovnikov
Liudmila Y Rozhinskaya
Larisa K Dzeranova
Ivan I Dedov
DOI:10.1038/bonekey.2016.42
Abstract
The aim of this study was to evaluate the diagnostic performance of osteocalcin (OC), as measured by automated electrochemiluminescence immunoassay (ECLIA), in identifying Cushing’s syndrome (CS) in two separate populations: among obese and overweight subjects and among women of postmenopausal age with osteoporosis. Among the 106 referral patients with obesity, CS was confirmed in 42 cases. The patients of the referred population provided late-night salivary cortisol (LNSC), underwent low-dose dexamethasone suppression testing (DST) and were further evaluated until CS was pathologically confirmed. A threshold of OC—8.3 ng ml−1 differentiated CS among obese and overweight subjects with a sensitivity of 73.8% (95% confidence interval (CI) 58.9–84.7) and a specificity of 96.9% (95% CI 89.3–99.1). The total area under the receiver operating characteristic curve (AUC) was 0.859 (95% CI 0.773–0.945), which was lower than LNSC or DST (P=0.01). In the retrospective portion of the study, the OC levels were evaluated in 67 subjects with newly diagnosed postmenopausal osteoporosis and in 23 patients (older than 45) with newly diagnosed CS and osteoporosis (presence of low traumatic fractures or T-score P–2.5). The diagnostic performance of OC for osteoporosis due to CS was within an AUC of 0.959 (95% CI 0.887–1.00). A threshold for OC of 8.3 ng ml-1 yielded a sensitivity of 95.4% (95% CI 78.2–99.2%) and a specificity of 98.5% (95% CI 92.0–99.7%). Thus, osteocalcin could be used in the diagnostic testing for endogenous hypercortisolism in patients referred to exclude CS and to identify CS among patients of postmenopausal age with osteoporosis.
This work is licensed under a
Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.